

Datasheet for WM115-01-0001**WM115 Viable Cells****Overview**

Description:	WM115 Viable Cells - WM115-01-0001
Item No.:	WM115-01-0001
Size:	1 million cells
Applications:	Cellular Assay, IF, WB
Origin:	Human

Product Details

Background:	WM115 is a tumorigenic (VGP) primary melanoma cell line with competence for metastasis. This cell line was established from a metastatic site (right anterior leg) in a 55-year-old female with superficial spreading melanoma. The subject displayed VGP with a Clark level III tumor with thickness of 2.24mm. This cell line features the specific V600D (Val600Asp) mutation at codon 600 in the BRAF gene. This cell line also expresses PTEN loss of function including hemizygous deletion. This cell line was derived from the same patient as the cell lines WM239A, WM165-1 and WM266-4. WM115 cell line originated from the primary tumor, and WM239A, WM165-1 and WM266-4 were from individual lymph-node metastases. WM115 cell line is wild type for N-RAS, c-KIT, and CDK4 genes. WM115 cells produce xenograft tumors when injected into immunocompromised mice.
Synonyms:	Melanoma, patient derived tumor, tumor models, skin cancer, xenograft, Human melanoma tumor cells
Species of Origin:	Human

Target Details

Purity/Specificity:	Cells are sterile, validated by short tandem repeat profiling, and are tested as negative for mycoplasma. It is recommended that cell lines are tested for mycoplasma contamination and short tandem repeat (STR) profiling every 10 passages or each time a frozen seed stock is made. See cell culture protocol for additional details.
Relevant Links:	<ul style="list-style-type: none">• Cell Line EULA• Melanoma Cell Culture Protocol

Application Details

Suggested Applications:	Cellular Assay, IF, WB (Based on references)
Application Note:	The key applications of these cell lines include genetic studies, xenograft production, drug testing, and drug target discovery. These cell line models can be used in various biological assays, and for identifying critical target genes, and cell signaling pathways.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.

Cell Line Data

Cell Line:	Human Melanoma
Product Type:	Viable Cells
Cell Viability:	Yes
Stage:	VGP
BRAF:	V600D
CDK4:	WT
C-Kit:	WT
N-RAS:	WT
PTEN:	Hemizygous Deletion
Paired:	Yes
Medium:	Tumor Specialized Media with 2% HI-FBS
Sub-culture:	Cells should be maintained between 30 – 95% confluence in tumor specialized medium with 2% FBS; split cultures 1:3 every 7 days using 0.25% trypsin/EDTA. This cell line has a doubling time of 36-48 hours which may change slightly with the type of media used.
Incubation:	36°C with 5% CO ₂


Formulation

Physical State:	Frozen Cell Suspension
Concentration:	1.0 million cells/mL Count By Hemocytometer
Buffer:	None
Preservative:	None
Stabilizer:	None

Shipping & Handling


Shipping Condition:	Dry Ice
Storage Condition:	Cells are frozen with 90% FBS/10% DMSO solution at about 1×10^6 cells/ml. Store vial in liquid nitrogen upon arrival.
Expiration:	Expiration date is two (2) years from date of receipt.

Images




Western Blot

PPAR γ expression and rosiglitazone impact in human melanoma. D, Expression of PPAR γ in human melanocytes and in melanoma cell lines representative of the disease progression, determined by RT-qPCR (top) and by Western blot (bottom). RT-qPCR: open circles are means of technical triplicates from one experiment. Columns are means of at least two independent experiments. Western blot: two different exposure times (short and long) of the same Western blot are shown; PPAR γ protein was quantified based on the short exposure time (GAPDH, loading control). Fig 1. PMID: 30185551.



Viable cell growth

Established WM115 viable cell growth in culture using appropriate Tumor Specialized Media with 2%FBS.

**Flask**

Human melanoma tumor cells with known gene mutations, disease stage, STR, and RPPA profiling

References

- Liu Q et al. Androgen drives melanoma invasiveness and metastatic spread by inducing tumorigenic fucosylation. *Nat Commun.* (2024)
- Eriksson I et al. Lysosomal Function and Intracellular Position Determine the Malignant Phenotype in Malignant Melanoma. *J Invest Dermatol.* (2023)
- Hanniford D et al. Epigenetic silencing of CDR1as drives IGF2BP3-mediated melanoma invasion and metastasis. *Cancer Cell.* (2021)
- Ayuso JM et al. Microfluidic model with air-walls reveals fibroblasts and keratinocytes modulate melanoma cell phenotype, migration, and metabolism. *Lab Chip.* (2021)
- Juraleviciute M et al. MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy. *Cancer Med.* (2021)
- Castro-Perez E et al. Melanoma Progression Inhibits Pluripotency and Differentiation of Melanoma-Derived iPSCs Produces Cells with Neural-like Mixed Dysplastic Phenotype. *Stem Cell Reports.* (2019)
- Pich C et al. Induction of paracrine signaling in metastatic melanoma cells by PPAR γ agonist rosiglitazone activates stromal cells and enhances tumor growth. *Cancer Res.* (2018)

Disclaimer

No test method can provide total assurance that the hepatitis B virus, hepatitis C virus, human immunodeficiency virus, or any other infectious agents are absent. Thus, all blood products, including purified proteins derived from human blood sources, should be handled at Biosafety Level 2 as recommended by the CDC\NIH manual entitled Biosafety in Microbiological and Biomedical Laboratories for potentially infectious human serum, blood specimens or proteins derived from same. Source material for the human blood product supplied to your facility has been tested for the detection of HIV antibody, Hepatitis B surface antigen, antibody to Hepatitis C, HIV 1 antigen(s), antibody to HTLV - I/II, and syphilis by FDA guidelines. All units were found to be non-reactive/negative for these tests. All human blood source material is collected in FDA licensed centers and is tested with FDA approved test kits.

Cell Line Limited Use License Required. THIS PRODUCT IS SUBJECT TO AN END-USER LICENSE AGREEMENT (EULA). BY ACCEPTING THIS PRODUCT, RECIPIENT AGREES TO BE BOUND BY THE TERMS OF USE SET FORTH BELOW and SET FORTH IN THE EULA. THIS PRODUCT IS FOR IN VITRO RESEARCH USE ONLY. THERAPEUTIC, DIAGNOSTIC, OR VETERINARY USE IS PROHIBITED. This product may not be resold or transferred by the recipient and may be used only by the recipient, in the recipient's facility and only for research use and other uses specifically permitted by the EULA. No other commercial use is allowed. "Commercial Use" means any and all uses of this product by recipient or others for monetary or other consideration, including providing services, supplying information or data to unaffiliated third parties, and resale or transfer of this product for any use. Recipient has no right to modify, derivatize, genetically engineer or otherwise create variations of this product or associated cells or cell lines. ROCKLAND AND WISTAR MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED, INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE PRODUCTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS. The terms set forth herein and in the EULA shall be governed by the laws of the Commonwealth of Pennsylvania, USA. To obtain a COMMERCIAL USE license for this product, please contact Rockland Immunochemicals, Inc. Please contact a technical service representative for more information. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.